Johnson & Johnson Explores $14.6 Billion Acquisition of Intra-Cellular Therapies at JPM25

Jan 13, 2025, 12:57 PM

Johnson & Johnson is exploring a potential acquisition of Intra-Cellular Therapies, a biopharmaceutical company co-founded in 2002 by Sharon Mates based on Nobel laureate Paul Greengard's research, in what could be one of the largest biotech deals in recent years valued at $14.6 billion. The discussions are ongoing, and no deal is certain, but the move could see Johnson & Johnson expand its portfolio in the biopharma sector. Intra-Cellular Therapies, with a market value of approximately $10 billion, is known for its drug Caplyta, which was first FDA-approved in December 2019. The acquisition, if completed, would mark a significant move in the healthcare industry, which has seen increased merger and acquisition activity. CEO Sharon Mates and the board have agreed to sell the company at the JPM25 conference.